Toxicology of the immune system / Leigh Ann Burns Naas.

Format:

Video

Author/Creator:

Burns Naas, Leigh Ann, author.

Language:

English

Subjects (All):

Immunotoxicology.

Toxicology.

Physical Description:

1 streaming video file (67 min.) : sound, color

Place of Publication:

London, England : Henry Stewart Talks Ltd, 2011.

System Details:

video file

Contents:

Introduction

Lesson objectives

Why the immune system?

Cornerstone of immunotoxicology

Possible consequences of immunomodulation

The immune system isn't confined to one site

T and B cell development

Average life span of blood cells

Innate vs. acquired immunity

Division of acquired immunity

The immune system can be targeted directly

The immune system can be targeted indirectly

Assessment of immunocompetence

Toxicology methods to assess immunocompetence

Suggested lymph nodes for histopathology

Non-functional assessment

Approaches to assessing immunotoxicity

Methods to assess immunocompetence (1)

Cell-mediated cytotoxicity

In vitro NK cell assay

Methods to assess immunocompetence (2)

Delayed-type hypersensitivity (DTH)

The DTH response

Local lymph node assay

Methods to assess immunocompetence (3)

T-dependent antibody response (TDAR) (1)

T-dependent antibody response (2)

Methods to assess immunocompetence (4)

Predictability of immune tests

Testing configurations

The immune system in regulatory toxicology testing

Regulatory immunotoxicology historical timeline (1)

Global regulatory considerations for new drugs

Overview of the 2002 FDA guidance

ICH S8: adverse (unintended) immunomodulation

ICH S8 objectives

ICH S8: recommended immunotoxicity evaluation

ICH S8: weight of evidence (WoE) review

Typical leukograms in animals / humans

A few words about stress

The WoE assessment should also include

Final factors to consider

Key points for data interpretation

Determination of a "cause for concern"

Cause for concern: immunotoxicity studies

ICH S8: immune evaluation consideration (1)

Regulatory immunotoxicology historical timeline (2)

Study designs for the rodent TDAR

Study designs for the NHP TDAR

General aspects of study designs (1)

General aspects of study designs (2)

ICH S8: immune evaluation consideration (2)

Models for host resistance

Host resistance assays

Consider additional immunotoxicity testing

Possible diagnostic and/or functional follow-up (1)

Possible diagnostic and/or functional follow-up (2)

Immune-mediated disease

What is immune-mediated disease?

Adverse drug reactions

Type 1 hypersensitivity

Type 2 hypersensitivity

Type 3 hypersensitivity

Autoimmunity / autoimmune disease

Drug-induced autoimmunity

Theories of drug-induced autoimmunity (1)

Theories of drug-induced autoimmunity (2)

Are there predictive models for autoimmunity?

Risk evaluation

What does It mean to humans?

Risk assessment in immunotoxicology

Challenges in assessing risk (1)

The "at risk" population

Challenges in assessing risk (2)

What is adverse?

How do we deal with the uncertainties?

Acknowledgments

References.

Notes:

Description based on publisher supplied metadata and other sources.

Retrieved April 13, 2024, from https://hstalks.com/bs/2068/.